From May 28th to 29th, 2026, the "Empowerment Service Conference of the Pharmaceutical Circulation Professional Committee of the China Nonprescription Medicines Association - Dabo Fair (Shaanxi Station)" was launched in Xi'an. The forum, themed "Shaping a New Landscape for Pharmaceutical Retail Growth," brought together over 300 industry experts, brand enterprises, and chain store elites to conduct in-depth discussions on topics such as policy interpretation, category upgrading, and digital operations.
Changchun Renmin Pharmaceutical Group, representing branded pharmaceutical companies, showcased over 10 premium traditional Chinese medicines, including those for colds/respiratory systems, rheumatism and bone injuries, and tonics. This attracted numerous chairmen and purchasing managers from chain pharmacies in Shaanxi Province to stop and exchange ideas, engaging in one-on-one discussions on practical cooperation in areas such as product sales and terminal empowerment. The group's superior product quality and professional service capabilities received high praise from the attendees, opening a new chapter for expanding into the Northwest market.
At the gala dinner on May 28th, the forum organizing committee solemnly presented several industry honors. Changchun Renmin Pharmaceutical Group won the "Strategic Cooperation Enterprise Award" for its deep collaboration and outstanding contributions in the field of pharmaceutical marketing. This award fully affirms the company's long-term commitment to quality and its active empowerment of end-user partners, and also marks its setting a benchmark in business cooperation and resource sharing.
As a long-established traditional Chinese medicine enterprise rooted in Northeast China and radiating across the country, Changchun Renmin Pharmaceutical has always adhered to the principle of quality as its foundation. Taking advantage of the China International Pharmaceutical Industry Expo (Shaanxi) station, the company not only showcased its core product strength but also established close ties with chain partners in Northwest China. In the future, the company will continue to deepen its focus on core traditional Chinese medicine categories, increase investment in regional market services, and work hand in hand with partners to build a new ecosystem for pharmaceutical retail, contributing to the industry's high-quality growth.